Loading...
Gene therapy, CRISPR, synthetic biology, and emerging platforms—what's real, what's hype, and what translates.
Graduate student enrollment in U.S. biomedical programs rose by 1.5% in fall 2025 compared to the previous year, despite ongoing funding turmoil in the research sector.
Graduate student enrollment in U.S. biomedical programs rose by 1.5% in fall 2025 compared to the previous year, despite ongoing funding turmoil in the research sector.
READ MORE
Aktis Oncology has launched its 2026 debut with a significant IPO raise of $318 million aimed at advancing its pipeline of 'miniprotein' radioconjugates for targeted cancer radiation therapy.
Eric Green, who directed genomics at NIH, is set to bring his expertise to Illumina’s leadership as the new Chief Medical Officer.
A key scientist behind the successful Baby KJ gene therapy has launched Aurora Therapeutics, aiming to scale personalized CRISPR-based treatments for rare diseases.
Rampart Bioscience, developing a novel non-viral vector gene therapy platform, has ceased operations less than two years post-launch.
Alveus Therapeutics launches with $160 million to advance a pipeline targeting obesity, aiming at GLP-1 and GIP receptors with novel dosing advantages over competitors.
Alveus Therapeutics emerges with substantial funding to develop next-generation obesity drugs targeting GLP-1 and GIP pathways.
GSK’s antisense oligonucleotide therapy bepirovirsen achieved its primary endpoints in Phase 3 trials, showing promise as a functional cure for chronic hepatitis B.
GSK’s antisense oligonucleotide therapy bepirovirsen has demonstrated functional cure rates for chronic hepatitis B in two Phase 3 studies.
China is projected to overtake the United States in biotechnology innovation soon, signaling a major shift in the global biotech landscape.
Arrowhead Pharmaceuticals announced early study results demonstrating their gene-silencing candidates effectively reduce fat in people with obesity.
